Citadel Advisors
VECT

Citadel Advisors’s VectivBio Holding AG Ordinary Shares VECT Stock Holding History

Citadel Advisors’s Portfolio VECT Stock Details VECT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,306
Closed -$22K – 15624
2023
Q2 		$22K Sell
1,306
-3,966,231
-100% -$52.1M ﹤0.01% 12643
2023
Q1 		$34.1M Sell
3,967,537
-298
-0% -$2.46K 0.01% 1422
2022
Q4 		$34.2M Buy
3,967,835
+822,584
+26% +$6.62M 0.01% 1434
2022
Q3 		$18.9M Buy
3,145,251
+2,014
+0.1% +$10.9K ﹤0.01% 1935
2022
Q2 		$17M Buy
3,143,237
+420,591
+15% +$2.26M ﹤0.01% 2024
2022
Q1 		$12.8M Buy
2,722,646
+1,830
+0.1% +$9.56K ﹤0.01% 2581
2021
Q4 		$13.4M Sell
2,720,816
-547
-0% -$2.7K ﹤0.01% 2586
2021
Q3 		$20.7M Sell
2,721,363
-4,404
-0.2% -$37.7K ﹤0.01% 1950
2021
Q2 		$31.2M Buy
+2,725,767
New +$41.4M 0.01% 1568

Other funds holding VECT

RCM
Regency Capital Management Honolulu, Hawaii $224M AUM 26.03% 1-Year Est. Return
SOW
State of Wyoming Cheyenne, Wyoming $844M AUM 37.96% 1-Year Est. Return

Citadel Advisors's VECT Position: Q3 2023 in Review

Citadel Advisors sold out of VectivBio Holding AG Ordinary Shares (VECT) in Q3 2023, closing a stake of 1,306 shares — an estimated $22K sold.

Citadel Advisors first reported a position in VECT in Q2 2021 and held it in 9 quarters. The position peaked at $34.2M in Q4 2022. 2 funds tracked by Wall St. Rank hold VECT as of Q3 2023.

  • Citadel Advisors reported no remaining VectivBio Holding AG Ordinary Shares position as of Q3 2023 after selling out during the quarter.
  • Citadel Advisors sold 1,306 VectivBio Holding AG Ordinary Shares shares in Q3 2023, an estimated $22K.
  • Citadel Advisors first reported a position in VectivBio Holding AG Ordinary Shares in Q2 2021 and held it in 9 quarters.
  • Citadel Advisors's VectivBio Holding AG Ordinary Shares position peaked at $34.2M in Q4 2022.
  • 2 funds tracked by Wall St. Rank held VectivBio Holding AG Ordinary Shares as of Q3 2023.

Based on Citadel Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.